Titre : Cellules A549

Cellules A549 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Preliminary Data
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Cellules A549 : Questions médicales les plus fréquentes", "headline": "Cellules A549 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Cellules A549 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-28", "dateModified": "2025-03-25", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Cellules A549" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Cellules épithéliales", "url": "https://questionsmedicales.fr/mesh/D004847", "about": { "@type": "MedicalCondition", "name": "Cellules épithéliales", "code": { "@type": "MedicalCode", "code": "D004847", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.436" } } }, "about": { "@type": "MedicalCondition", "name": "Cellules A549", "alternateName": "A549 Cells", "code": { "@type": "MedicalCode", "code": "D000072283", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Wenfei Zhao", "url": "https://questionsmedicales.fr/author/Wenfei%20Zhao", "affiliation": { "@type": "Organization", "name": "Department of Respiratory, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China." } }, { "@type": "Person", "name": "Hongyun Li", "url": "https://questionsmedicales.fr/author/Hongyun%20Li", "affiliation": { "@type": "Organization", "name": "Department of Respiratory, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China." } }, { "@type": "Person", "name": "Shanshan Yang", "url": "https://questionsmedicales.fr/author/Shanshan%20Yang", "affiliation": { "@type": "Organization", "name": "Department of Respiratory, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China." } }, { "@type": "Person", "name": "Di Guo", "url": "https://questionsmedicales.fr/author/Di%20Guo", "affiliation": { "@type": "Organization", "name": "Department of Respiratory, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China." } }, { "@type": "Person", "name": "Jing Chen", "url": "https://questionsmedicales.fr/author/Jing%20Chen", "affiliation": { "@type": "Organization", "name": "Department of Respiratory, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Cardiovascular Disease Risk in a Cohort of Virologically Suppressed People Living with HIV Switching to Doravirine: Preliminary Data from the Real Life.", "datePublished": "2022-10-19", "url": "https://questionsmedicales.fr/article/36166220", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1089/AID.2022.0050" } }, { "@type": "ScholarlyArticle", "name": "Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study.", "datePublished": "2023-10-11", "url": "https://questionsmedicales.fr/article/37821952", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13075-023-03182-9" } }, { "@type": "ScholarlyArticle", "name": "COVID-19 pandemic increases the occurrence of nursing burnout syndrome: an interrupted time-series analysis of preliminary data from 38 countries.", "datePublished": "2023-04-11", "url": "https://questionsmedicales.fr/article/37060733", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.nepr.2023.103643" } }, { "@type": "ScholarlyArticle", "name": "Safety use of high frequency oscillatory ventilation in transport of newborn infants affected by severe respiratory failure: preliminary data in central Tuscany.", "datePublished": "2022-06-10", "url": "https://questionsmedicales.fr/article/35689179", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12887-022-03393-0" } }, { "@type": "ScholarlyArticle", "name": "An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.", "datePublished": "2022-06-28", "url": "https://questionsmedicales.fr/article/35760939", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10067-022-06253-5" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Cellules", "item": "https://questionsmedicales.fr/mesh/D002477" }, { "@type": "ListItem", "position": 3, "name": "Cellules épithéliales", "item": "https://questionsmedicales.fr/mesh/D004847" }, { "@type": "ListItem", "position": 4, "name": "Cellules A549", "item": "https://questionsmedicales.fr/mesh/D000072283" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Cellules A549 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Cellules A549", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Cellules A549", "description": "Comment identifier les cellules A549 en laboratoire ?\nQuelles techniques sont utilisées pour étudier les cellules A549 ?\nLes cellules A549 sont-elles tumorales ?\nPeut-on détecter des marqueurs spécifiques dans les A549 ?\nLes cellules A549 sont-elles sensibles à des médicaments ?", "url": "https://questionsmedicales.fr/mesh/D000072283?mesh_terms=Preliminary+Data&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Cellules A549", "description": "Quels symptômes sont associés aux cellules A549 ?\nLes cellules A549 peuvent-elles simuler des symptômes humains ?\nComment les A549 aident-elles à comprendre les symptômes du cancer ?\nLes cellules A549 montrent-elles des signes de stress cellulaire ?\nPeut-on observer des symptômes de résistance dans les A549 ?", "url": "https://questionsmedicales.fr/mesh/D000072283?mesh_terms=Preliminary+Data&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Cellules A549", "description": "Les cellules A549 aident-elles à la prévention du cancer ?\nComment les A549 contribuent-elles à la recherche préventive ?\nPeut-on utiliser les A549 pour étudier des facteurs de risque ?\nLes A549 sont-elles utiles pour la recherche sur le tabagisme ?\nComment les A549 aident-elles à comprendre la prévention des maladies ?", "url": "https://questionsmedicales.fr/mesh/D000072283?mesh_terms=Preliminary+Data&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Cellules A549", "description": "Quels traitements sont testés sur les cellules A549 ?\nLes A549 sont-elles utilisées pour des essais cliniques ?\nComment les A549 aident-elles à développer de nouveaux traitements ?\nLes cellules A549 peuvent-elles prédire la réponse au traitement ?\nQuels agents sont souvent testés sur les A549 ?", "url": "https://questionsmedicales.fr/mesh/D000072283?mesh_terms=Preliminary+Data&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Cellules A549", "description": "Quelles complications peuvent être étudiées avec les A549 ?\nLes A549 peuvent-elles simuler des complications pulmonaires ?\nComment les A549 aident-elles à comprendre les complications du cancer ?\nPeut-on étudier la résistance aux traitements avec les A549 ?\nLes A549 sont-elles impliquées dans des complications métaboliques ?", "url": "https://questionsmedicales.fr/mesh/D000072283?mesh_terms=Preliminary+Data&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Cellules A549", "description": "Quels facteurs de risque sont étudiés avec les A549 ?\nLes A549 aident-elles à identifier des facteurs génétiques ?\nComment les A549 sont-elles utilisées pour étudier l'environnement ?\nPeut-on étudier l'alimentation avec les A549 ?\nLes A549 sont-elles utiles pour étudier le stress oxydatif ?", "url": "https://questionsmedicales.fr/mesh/D000072283?mesh_terms=Preliminary+Data&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier les cellules A549 en laboratoire ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules A549 peuvent être identifiées par leur morphologie et leur croissance en culture." } }, { "@type": "Question", "name": "Quelles techniques sont utilisées pour étudier les cellules A549 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les techniques incluent la microscopie, la cytométrie en flux et les tests de viabilité cellulaire." } }, { "@type": "Question", "name": "Les cellules A549 sont-elles tumorales ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les cellules A549 proviennent d'un adénocarcinome, ce qui les rend tumorales." } }, { "@type": "Question", "name": "Peut-on détecter des marqueurs spécifiques dans les A549 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des marqueurs comme le CD44 et le p53 peuvent être analysés dans les A549." } }, { "@type": "Question", "name": "Les cellules A549 sont-elles sensibles à des médicaments ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont souvent utilisées pour tester la sensibilité aux chimiothérapies." } }, { "@type": "Question", "name": "Quels symptômes sont associés aux cellules A549 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules A549 ne présentent pas de symptômes, car elles sont in vitro." } }, { "@type": "Question", "name": "Les cellules A549 peuvent-elles simuler des symptômes humains ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent être utilisées pour étudier des symptômes liés aux maladies pulmonaires." } }, { "@type": "Question", "name": "Comment les A549 aident-elles à comprendre les symptômes du cancer ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'étudier la réponse des cellules tumorales aux traitements et aux facteurs de croissance." } }, { "@type": "Question", "name": "Les cellules A549 montrent-elles des signes de stress cellulaire ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent montrer des signes de stress en réponse à des agents cytotoxiques." } }, { "@type": "Question", "name": "Peut-on observer des symptômes de résistance dans les A549 ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent être utilisées pour étudier la résistance aux médicaments anticancéreux." } }, { "@type": "Question", "name": "Les cellules A549 aident-elles à la prévention du cancer ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Indirectement, elles sont utilisées pour étudier les mécanismes de la carcinogenèse." } }, { "@type": "Question", "name": "Comment les A549 contribuent-elles à la recherche préventive ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'identifier des biomarqueurs et des cibles pour la prévention du cancer." } }, { "@type": "Question", "name": "Peut-on utiliser les A549 pour étudier des facteurs de risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont utilisées pour étudier l'impact de divers facteurs environnementaux sur le cancer." } }, { "@type": "Question", "name": "Les A549 sont-elles utiles pour la recherche sur le tabagisme ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont souvent utilisées pour étudier les effets du tabagisme sur les cellules pulmonaires." } }, { "@type": "Question", "name": "Comment les A549 aident-elles à comprendre la prévention des maladies ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'explorer les mécanismes de protection et les interventions préventives." } }, { "@type": "Question", "name": "Quels traitements sont testés sur les cellules A549 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements anticancéreux et les thérapies ciblées sont souvent testés sur ces cellules." } }, { "@type": "Question", "name": "Les A549 sont-elles utilisées pour des essais cliniques ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, elles sont utilisées pour des études précliniques et non pour des essais cliniques directs." } }, { "@type": "Question", "name": "Comment les A549 aident-elles à développer de nouveaux traitements ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'évaluer l'efficacité et la toxicité des nouveaux composés thérapeutiques." } }, { "@type": "Question", "name": "Les cellules A549 peuvent-elles prédire la réponse au traitement ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent fournir des indications sur la réponse aux traitements, mais ne sont pas définitives." } }, { "@type": "Question", "name": "Quels agents sont souvent testés sur les A549 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des agents chimiothérapeutiques comme le cisplatine et des inhibiteurs de tyrosine kinase." } }, { "@type": "Question", "name": "Quelles complications peuvent être étudiées avec les A549 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'étudier les complications liées aux traitements du cancer et aux métastases." } }, { "@type": "Question", "name": "Les A549 peuvent-elles simuler des complications pulmonaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont utilisées pour modéliser des complications comme la fibrose pulmonaire." } }, { "@type": "Question", "name": "Comment les A549 aident-elles à comprendre les complications du cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'étudier les interactions entre les cellules tumorales et le microenvironnement." } }, { "@type": "Question", "name": "Peut-on étudier la résistance aux traitements avec les A549 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont souvent utilisées pour comprendre les mécanismes de résistance aux traitements." } }, { "@type": "Question", "name": "Les A549 sont-elles impliquées dans des complications métaboliques ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent être utilisées pour étudier les effets métaboliques des traitements anticancéreux." } }, { "@type": "Question", "name": "Quels facteurs de risque sont étudiés avec les A549 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme le tabagisme, l'exposition à des agents chimiques et la pollution." } }, { "@type": "Question", "name": "Les A549 aident-elles à identifier des facteurs génétiques ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent être utilisées pour étudier l'expression génique liée à des prédispositions au cancer." } }, { "@type": "Question", "name": "Comment les A549 sont-elles utilisées pour étudier l'environnement ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'évaluer l'impact des toxines environnementales sur les cellules pulmonaires." } }, { "@type": "Question", "name": "Peut-on étudier l'alimentation avec les A549 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Indirectement, elles peuvent être utilisées pour explorer l'impact des nutriments sur le cancer." } }, { "@type": "Question", "name": "Les A549 sont-elles utiles pour étudier le stress oxydatif ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont souvent utilisées pour examiner les effets du stress oxydatif sur les cellules." } } ] } ] }

Sources (10000 au total)

Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study.

Upadacitinib (UPA) is a selective JAK inhibitor recently approved for the treatment of psoriatic arthritis (PsA). In this post-approval study, we aimed to evaluate the effectiveness and safety of UPA ... One hundred and twenty-six patients with PsA treated with UPA were enrolled in 10 Italian centres. UPA effectiveness outcomes, such as the proportion of patients with MDA status, DAPSA remission, and ... At baseline, 124/126 (98%) and 54/126 (43%) patients showed peripheral and axial involvement, respectively; 110 (87%) patients were intolerant or resistant to biologic DMARDs. At 24 weeks, MDA status,... This is one of the first real-life studies supporting the effectiveness of UPA and its safety profile in PsA patients. Furthermore, the study identifies predictors of MDA response to UPA treatment at ...

COVID-19 pandemic increases the occurrence of nursing burnout syndrome: an interrupted time-series analysis of preliminary data from 38 countries.

To evaluate the trends in nursing burnout rates before and during the coronavirus 2019 restrictions.... Meta-analysis was used to extract the data on global nursing burnout from 1 Jan. 2010-15 Dec. 2022. An interrupted time-series analysis using segmented ordinary least squares (OLS) regression models w... Before the epidemic (April 2020), the nursing burnout rate rose with 0.0007497 (95% CI: 0.0000316, 0.0014677, t = 2.07, P = 0.041) per month. The trend of nursing burnout rate has increased by 0.02310... The study indicated that the Covid-19 restrictions had an impact on nursing burnout, increasing the occurrence of nursing burnout syndrome....

Safety use of high frequency oscillatory ventilation in transport of newborn infants affected by severe respiratory failure: preliminary data in central Tuscany.

Neonatal Emergency Transport Services play a fundamental role in neonatal care. Stabilization before transport of newborns suffering from severe respiratory failure is often a challenging problem and ... A retrospective analysis was performed reviewing medical records of the neonates transported by Meyer Children Hospital's Neonatal Transport Service between May 2018 and December 2020, and newborns tr... Out of the approximate 400 newborns transported during the analysis period, 9 were transported in HFOV. We did not find any statistically significant difference in vital parameters, hemogas-analytical... The interest of our report is in the possibility of using HFOV during inter-hospital neonatal transfer. As far as our experience has shown, HFOV appears to be safe for the transportation of newborns w...

An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.

To evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with rheumatic and immune-mediated inflammatory diseases (IMIDs) in Argentina: the SAR-CoVAC registry.... SAR-CoVAC is a national, multicenter, and observational registry. Adult patients with rheumatic or IMIDs vaccinated for SARS-CoV-2 were consecutively included between June 1 and September 17, 2021. So... A total of 1234 patients were included, 79% were female, with a mean age of 57.8 (SD 14.1) years. The most frequent diseases were rheumatoid arthritis (41.2%), osteoarthritis (14.5%), psoriasis (12.7%... In this national cohort of patients, the most common vaccines used were Gam-COVID-Vac and ChAdOx1 nCoV-19. A quarter of the patients presented an AE and 5.1% presented SARS-CoV-2 infection after vacci... This study has been registered in ClinicalTrials.gov under the number: NCT04845997. Key Points • This study shows real-world data about efficacy and safety of SARS-CoV-2 vaccination in patients with r...

Does Compliance or Cost Regulate Effectiveness of Notched Sound Therapy Phone Applications for Tinnitus Relief? Preliminary Data of a Prospective Randomized Control Trial.

The objective of this study is to evaluate compliance with and effectiveness of notched sound therapy (NST) administered through a mobile application in improving symptoms of patients experiencing chr... A prospective randomized control trial was done.... The study was done at a tertiary referral center.... Adult patients with tinnitus were monitored.... Patients were randomized at enrollment to either the NST or a standard of care (SOC) group. NST arm included, in addition to SOC, a free subscription to NST mobile application, whereas the SOC arm inc... The main outcome measures were continued enrollment in study, compliance with the therapy, frequency and duration of therapy use, and change from the baseline in the Tinnitus Handicap Inventory (THI).... Patients in the NST group were 2.25 times more likely to use the NST application for 3 months postenrollment. Only 33% of users in the NST group listened for the prescribed 2 h/d compared with 0% of u... Monitoring tinnitus for 3 months leads to a decrease in subjective symptoms regardless of NST use. Patients who received a free subscription to the application were more likely to continue with therap...

QT and Tpeak-Tend interval variability: Predictive electrical markers of hospital stay length and mortality in acute decompensated heart failure. Preliminary data.

As previously reported, an increased repolarization temporal imbalance induces a higher risk of total/cardiovascular mortality.... The aim of this study was to assess if the electrocardiographic short period markers of repolarization temporal dispersion could be predictive of the hospital stay length and mortality in patients wit... Mean, standard deviation (SD), and normalized variance (VN) of QT (QT) and Tpeak-Tend (Te) were obtained on 5-min ECG recording in 139 patients hospitalized for acutely decompensated CHF, subgrouping ... We observed an increase of short-period repolarization variables (TeSD and TeVN, p < .05), a decrease of blood pressure (p < .05), lower ejection fraction (p < .05), and higher plasma level of biomark... A longer hospital stay is considered a clinical surrogate of CHF severity, we confirmed this finding. Therefore, these electrical and simple parameters could be used as noninvasive, transmissible, ine...

Pertussis, diphtheria, and tetanus antibodies seroprevalence in pregnant women and neonates, as a preliminary data for introduction of preconception or prenatal DTaP vaccination among Japanese society.

An increasing number of countries have been introducing acellular pertussis vaccination during pregnancy for the prevention of neonatal pertussis. In response to the fact that infantile pertussis case...